

Image of Ebola viruses exiting host cells - Courtesy of NIAID

ANNUAL SHAREHOLDER MEETING

JIM JOYCE - FOUNDER & CEO

NASDAQ - AEMD / MARCH 28, 2018

aethlon MEDICAL, INC.

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE

aethlon MEDICAL, INC.

Mission

To Save Lives

Our Lead therapeutic Candidate

A first-in-class therapeutic technology

The Hemopurifier®

A Broad-spectrum Virus Treatment Candidate

Designed for the single-use removal of infectious viruses from blood

aethlon MEDICAL, INC.

Summary Activity Report

January 2017 - March 2018

Summary Activity Report

January 2017 - March 2018

- **Capital Markets Activity**
  - Raised ~ $12 million (all equity - no debt instruments)
  - Increased daily market liquidity from < $100,000 per-day to >$500,000 per-day value
  - Increased shareholder base by > 50% (8000 + shareholders)

Summary Activity Report

January 2017 - March 2018

- **Corporate Governance**
  - Appointed new Directors with record of transitioning clinical-stage therapies to market
    - Dr. Charles Fisher
    - Sabrina Martucci-Johnson

Summary Activity Report

January 2017 - March 2018

- **Oncology**
  - Awarded National Cancer Institute (NCI) Contract
  - Teamed with exosome biology thought leaders from University of Pittsburgh and Mass General / Harvard
  - Objectives
    - Pre-clinical testing of our Hemopurifier to treat cancer
    - Isolation and release of tumor-derived exosomes to diagnose and monitor cancer progression

Summary Activity Report

January 2017 - March 2018

- **Exosome Sciences, Inc.** (Aethlon diagnostic subsidiary)
  - Establishment of IRB approval at the Translational Genomics Research Institute (TGEN) to support follow-on NFL & Control subject CTE/Tauopathy study
  - Formal launch of the ESI-TGEN study (TODAY)

Summary Activity Report

January 2017 - March 2018

- **Intellectual Property**
  - Expanded IP portfolio through multiple patent issuances and submissions
- **Manufacturing**
  - Established Quality Systems & cGMP to support the advancement of the Aethlon Hemopurifier

Summary Activity Report

January 2017 - March 2018

- **Hemopurifier Regulatory Activities**
  - Concluded U.S. FDA feasibility study (March 2017)
    - Submitted preliminary and final study reports, which were accepted by FDA
  - Submitted Expedited Access Pathway (EAP) application to FDA (August 2017)
    - Received EAP designation award from FDA (September 2017)
    - Subsequent transition to “Breakthrough Device” pathway (October 2017)
    - Conducted post EAP-Breakthough Device designation all-hands call with FDA
    - Filed FDA pre-submission application to request an informational meeting
    - Conducted information meeting at FDA headquarters on March 20, 2018

UNDER THE EAP - "BREAKTHROUGH DEVICE" DESIGNATION, THE FDA PERMITTED THE PROPOSED INDICATION FOR USE TO INCLUDE: ***"THE HEMOPURIFIER IS A SINGLE-USE DEVICE INDICATED FOR THE TREATMENT OF LIFE-THREATENING HIGHLY GLYCOSYLATED VIRUSES THAT ARE NOT ADDRESSED WITH AN APPROVED TREATMENT."***

The Aethlon Hemopurifier®

From theoretical concept to clinical reality

- First FDA pre-IDE meeting (2005)
  - Four investigational human studies (outside U.S.)
    - Treated HIV, HCV and ebola
  - >16 high-threat *in vitro* virus capture validations
- IDE clearance from FDA to Initiate U.S. feasibility study (2013)
- EUA to treat Ebola by FDA & Health Canada (2015)
- conclusion of FDA Human Feasibility study (2017)
- EAP - breakthrough device designation (2017)

The Hemopurifier® Aligns with current U.S. Government initiatives to protect citizens from high-threat Pathogens

aethlon MEDICAL, INC.

2017-18 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan

STATED PHEMCE OBJECTIVES INCLUDE

- **A FOCUS ON BROAD-SPECTRUM MEDICAL COUNTERMEASURES (MCMS) AGAINST:**
  - Known life-threatening viruses without an approved therapy
  - Unknown life-threatening viruses that evolve naturally or have been genetically engineered to be an agent of bioterrorism
  - Viruses that may be life-threatening to at-risk populations (children, pregnant women, immune-compromised) for which first-line therapies may not be indicated

- **WHEN POSSIBLE, PHEMCE WILL WILL PURSUE SUCH BROAD-SPECTRUM MCMS THAT MAY ALSO HAVE COMMERCIAL VIABILITY IN OTHER INDICATIONS. THE HEMOPURIFIER® MAY ALSO HAVE COMMERCIAL VIABILITY AGAINST:**
  - Latent viruses that are not well-addressed in immune-compromised individuals
  - Viruses that evolve resistance to approved antivirals

THE AETHLON HEMOPURIFIER®

FDA

EAP - BREAKTHROUGH DEVICE CANDIDATE TO TREAT LIFE-THREATENING VIRUSES

aethlon MEDICAL, INC.

TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE

aethlon MEDICAL, INC.

Mission

To Save Lives

9635 Granite Ridge Drive, Suite 100

San Diego, California 92123

858.459.7800

Nasdaq: AEMD

www.AethlonMedical.com

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com